A Panel of Plasma Biomarkers for Differential Diagnosis of Parkinsonian Syndromes

Qi Li†, Zhen Li†, Xiaoxuan Han, Xiao Shen, Fei Wang, Lipeng Bai, Zhuo Li, Rui Zhang, Yanlin Wang and Xiaodong Zhu*

Department of Neurology, Tianjin Neurological Institute, Tianjin Medical University General Hospital, Tianjin, China

Objective: The aim of our study is to explore the most reliable panel of plasma biomarkers for differential diagnosis of parkinsonian syndromes (PDSs). We selected five kinds of neurodegenerative proteins in plasma: neurofilament light chain (NfL), α-synuclein (α-syn), total tau, β-amyloid 42 (Aβ42) and β-amyloid 40 (Aβ40), and investigated the diagnostic value of these biomarkers.

Methods: A total of 99 plasma samples from patients with Parkinson’s disease (PD), multiple system atrophy (MSA), progressive supranuclear palsy, and age-matched healthy controls (HCs) were enrolled in our study. Plasma NfL, α-syn, total tau, Aβ42, and Aβ40 levels were quantified by ultrasensitive single molecule array immunoassay. We used logistic regression analyses to examine diagnostic accuracy of these plasma biomarkers. Disease severity was assessed by the modified Hoehn and Yahr staging scale, Unified Parkinson’s Disease Rating Scale part III (UPDRS III), and the Mini-Mental State Examination (MMSE), and subsequently, correlation analysis was performed.

Results: A combination of α-syn, Aβ42, Aβ40, Aβ42/40, and NfL could achieve a best diagnostic value in differentiating PDSs from HC and PD from HC, with an AUC of 0.983 and 0.977, respectively. By adding NfL to measurements of α-syn or Aβ42 or Aβ40 or Aβ42/40, the best discriminating panel was formed in differentiating atypical parkinsonian disorder (APD) and HC, and the discriminatory potential could reach a sensitivity of 100% and specificity of 100% (AUC = 1.000). For further distinguishing PD from APD, we found a combination of NfL, Aβ42, and total tau was the most reliable panel with equally high diagnostic accuracy. With respect to differentiating the subtypes of APD from one another, our results revealed that measurement of NfL, total tau, Aβ42, Aβ40, and Aβ42/40 was the best discriminating panel. Correlation analysis suggests that plasma Aβ42 levels were positively correlated to UPDRS part III scores in MSA. In terms of cognitive function, there was a relationship between plasma Aβ42/40 level and MMSE scores in patients with APD.

Conclusion: In our study, various combinations of plasma biomarkers have great potentialities in identifying PDSs, with important clinical utility in improving diagnostic accuracy. Plasma NfL may have added value to a blood-based biomarker panel for differentiating PDSs.

Keywords: Parkinsonian syndromes, Parkinson’s disease, biomarker, neurofilament light chain, panel
INTRODUCTION

Parkinson's disease (PD) is one of the most common neurodegenerative disorders. Because of the large overlap of clinical symptoms, characterized by bradykinesia in combination with rest tremor, rigidity, or both (Geut et al., 2020), it is difficult to differentiate PD from atypical parkinsonian disorders (APDs) in early stages, which are mainly involved in multiple system atrophy (MSA) and progressive supranuclear palsy (PSP). There is an urgent need for reliable biomarkers to achieve an early and effective differential diagnosis in parkinsonian syndromes (PDSs).

Key factor that complicates the differentiation among different PDSs is the accompanying pathology. Generally, the neuropathologies of PDSs can be classified into two clusters, α-synucleinopathy and tauopathy (Geut et al., 2020). It is universally acknowledged that a definite diagnosis with neuropathological confirmation is difficult to achieve. Therefore, biofluid biomarkers are the topical issues for the differential diagnoses. Several proteins associated with neurodegeneration, such as neurofilament light chain (NfL), α-synuclein (α-syn), total tau, β-amyloid 42 (Aβ42) and β-amyloid 40 (Aβ40), have been wildly studied as potential biomarkers for PDSs in cerebrospinal fluid (CSF) (Marques et al., 2019; Parnetti et al., 2019; Oosterveld et al., 2020). It is valuable to investigate a convenient blood-based biomarker panel for differential diagnosis in PDSs.

The aim of this study was to investigate whether plasma NfL, α-syn, total tau, Aβ42, Aβ40, and Aβ42/Aβ40 contribute to an optimal biomarker panel to differentiate the subtypes of PDSs from one another and controls, quantified by an ultrasensitive single molecule array (Simoa) immunoassay. Furthermore, we performed the correlation analysis of plasma biomarkers with clinical features of disease severity in patients with PD and APD.

MATERIALS AND METHODS

Study Participants

All participants were recruited from the movement disorders outpatient clinics of the General Hospital of Tianjin Medical University. We analyzed a total of 99 plasma samples from patients with PD (n = 45), MSA (n = 13), PSP (n = 8), and age-matched healthy controls (n = 33). Inclusion criteria for PD met the United Kingdom Parkinson's Disease Society Brain Bank (UKPDSBB) criteria (Hughes et al., 1992). We defined patients entering the study as having MSA, following the "Second consensus statement on the diagnosis of MSA" (Gilman et al., 2008), and diagnosis of PSP patients was established according to the National Institute for Neurological Disorders and Stroke/Society criteria for PSP (Osaki et al., 2004). HCs who were recruited from the local community at the same period and matched for age and education have no history of serious physical, neurological, psychiatric disorders, and alcohol or substance abuse. The research protocols were approved and performed in accordance with the guidelines of the Ethics Committee of the General Hospital of Tianjin Medical University. Written informed consent for scientific research purposes was obtained from all subjects.

Clinical Evaluation

The motor symptoms of patients were evaluated using the modified Hoehn and Yahr staging scale (H&Y stage) (Hoehn and Yahr, 1967) and Unified Parkinson's Disease Rating Scale part III (UPDRS III) (Goetz et al., 2008) as measurements of clinical parkinsonian severity, which was performed during off medication, more than 12 h after the last dose of dopaminergic therapy. Global cognitive function was examined with the Mini-Mental State Examination (MMSE).

Measurement of Plasma Biomarkers

Fasting blood samples were collected by peripheral venous blood into 10-mL EDTA tubes and centrifuged (2,500g for 15 min) within 1 h after collection, aliquoted, and stored in polypropylene tubes at ~80°C until analysis. The plasma levels of NfL, α-syn, total tau, Aβ42, and Aβ40 were measured by researchers who were blinded to the diagnosis and separately assayed via Simoa NfL Advantage kits (Quanterix, Lexington, MA, United States), Neurology 3-Plex A advantage kit (lot 502473), and α-syn discovery kit (Lot 502566) on the basis of manufacturer's introductions and standard procedures.

Statistical Analyses

All statistical analyses were performed with SPSS 22.0 (IBM, Inc., Armonk, NY, United States) and GraphPad Prism 9 (La Jolla, CA, United States). Shapiro–Wilk test was used to examine the Gaussian distribution of our data (p > 0.05). Numerical variables were displayed as mean ± SD. Comparisons of plasma biomarkers among different diagnostic groups were assessed by one-way analysis of variance (ANOVA), Kruskal–Wallis, and Mann–Whitney U test. Multiple linear regression analyses adjusted for age, sex, and disease duration were conducted to examine the differences among diagnostic groups. The correlation among plasma proteins and clinical outcomes was accessed by Spearman rank correlation analysis. The diagnostic accuracy was examined with receiver operating characteristic (ROC) curve analyses. To determine the optimal differentiating biomarker panel, we performed a binary logistic regression analysis. P < 0.05 was considered statistically significant.

RESULTS

Clinical Characteristics

A total of 99 participants consisting of 45 patients with PD, 13 patients with MSA, 8 patients with PSP, and 33 normal control subjects were enrolled in this study. Table 1 summarizes the characteristics and specific demographic data for all participants. The mean age of the four groups had no significant difference from each other (p = 0.05). In patients with APD, the motor severity (UPDRS part III scores and H–Y stage) was significantly greater than that in PD (p < 0.01).
Mean plasma biomarker levels among different diagnostic groups. To adjust for the potential confounding factors of age, sex, and disease duration, we performed multiple linear regression. After adjustment, we found that the plasma Aβ42, Aβ42/40, and α-syn levels were significantly higher in the PD group compared with HC (Aβ40: PD vs. HC: p < 0.0001; Aβ40/40: PD vs. HC: p < 0.0001; α-syn: PD vs. HC: p < 0.0001; Figures 1C–E). The levels of plasma total tau, Aβ42, and Aβ42/40 were significantly elevated in patients with PD compared with those in APD (total tau: PD vs. MSA: p < 0.01, PD vs. PSP: p < 0.05; Aβ42: PD vs. MSA: p < 0.0001, PD vs. PSP: p < 0.0001; Aβ42/40: PD vs. MSA: p < 0.0001, PD vs. PSP: p < 0.0001; Figures 1A,B,D). Moreover, the level of plasma NfL was significantly increased in patients with MSA and PSP when compared with PD (PSP, p < 0.0001; MSA, p < 0.0001) and controls (PSP, p < 0.0001; MSA, p < 0.0001). Plasma NfL concentrations in patients with MSA were clearly higher than those in PSP (p = 0.02) (Figure 1F). Only patients with PSP had an increased expression level of Aβ40 and α-syn compared with controls (Aβ40: p < 0.05; α-syn: p < 0.0001, Figures 1C,E).

Diagnostic Accuracy of Plasma Biomarkers

Discriminatory value of plasma NfL, total tau, Aβ42, Aβ40, Aβ42/40 and α-syn as a single biomarker and as part of plasma biomarker panel in differentiating PDSs (PD and APD) from HC is presented in Table 2. The biomarkers were selected to combine as a panel according to the level of AUC; that is, we selected the biomarkers to combine as a panel according to the ability of independently predicted diagnosis of individual biomarker.
specificity of 100 and 95.6%, respectively; PD vs. PSP: a sensitivity and specificity of 82.5 and 100%, respectively). As seen from Table 3, the best differentiating panel between PD and APD was formed by the combination of plasma NfL, Aβ42, and total tau, which yielded an ideal sensitivity and specificity of 100% (AUC = 1.000), whereas the combination of Aβ42 and total tau without NfL revealed an AUC of 0.963 with a sensitivity of 95% and a specificity of 91.1%.

Multiple System Atrophy vs. Progressive Supranuclear Palsy
Neurofilament light was the most reliable biomarker to differentiate MSA from PSP, which had a sensitivity of 78.3% and a specificity of 87.5% (AUC = 0.802; Table 4). The model of total tau, Aβ42, Aβ40, and Aβ42/40 could differentiate MSA from PSP with an AUC of 0.823. Now adding plasma NfL into the model, the best discriminatory panel was formed by the combination of NfL, total tau, Aβ42, Aβ40, and Aβ42/40 with an AUC of 1.000, a sensitivity of 100%, and a specificity of 100%.

A summary of the best single biomarker and panel in comparing different PDSs from one another and controls is presented in Table 5.

Correlation Between Plasma Biomarkers and Motor Severity
We investigated whether there was a relationship between plasma biomarkers and motor severity as measured by MDS-UPDRS part III and H&Y stage. According to Table 1, patients with APD had significantly worse motor dysfunction compared with PD patients (p < 0.01 by ANOVA). Correlation analysis revealed that plasma Aβ42 levels were positively correlated to UPDRS part III scores in patients with MSA (r = 0.589, p = 0.03; Figure 2). Other biomarkers were not correlated with UPDRS part III during “off” time in PDS patients.

Correlation Between Plasma Biomarkers and Cognitive Function
Previous studies have confirmed that β-amyloid contributed to the prediction of cognitive deterioration in other neurodegenerative diseases, just as PD, not limited to Alzheimer disease (AD). We next investigated the relevance between plasma biomarkers and cognitive status (MMSE) in each diagnostic group. By means of correlation analysis, we found that plasma Aβ42/40 level positively correlated with MMSE scores only in patients with APD (MSA: r = 0.583, p = 0.03; PSP: r = 0.763, p = 0.03; Figure 3).

DISCUSSION
In this study, we aimed to demonstrate whether plasma levels of NfL, α-syn, total tau, Aβ42, Aβ40, and Aβ42/40 integrated could be applied to identify PDSs. For this purpose, we measured the levels of several specific and meaningful biomarkers in
TABLE 2 | Discriminatory value of plasma NfL, total tau, Aβ42, Aβ40, Aβ42/40 and α-syn as a single biomarker and as part of plasma biomarker panel in differentiating PDS (PD and APD) from HC.

| Diagnostic groups | Predictor | AUC | Sensitivity | Specificity |
|-------------------|-----------|-----|-------------|-------------|
| PDS vs. HC | Single biomarker | | | |
| α-Syn | 0.889 | 80.0% | 93.9% |
| Aβ40 | 0.824 | 83.1% | 78.8% |
| Aβ42 | 0.800 | 70.8% | 87.9% |
| NfL | 0.694 | 46.2% | 97.0% |
| Aβ42/40 | 0.576 | 48.5% | 51.5% |
| Total tau | 0.513 | 83.1% | 33.3% |
| Biomarker panel | | | | |
| Aβ42, Aβ40, Aβ42/40, NfL, and α-syn | 0.983 | 98.5% | 93.9% |
| α-Syn, Aβ40, Aβ42/40, and NfL | 0.982 | 96.9% | 93.9% |
| α-Syn, Aβ40, and NfL | 0.980 | 93.8% | 97.0% |
| α-Syn, total tau, and NfL | 0.921 | 73.8% | 100% |
| PD vs. HC | Single biomarker | | | |
| Aβ42 | 0.925 | 93.1% | 87.9% |
| α-Syn | 0.875 | 73.3% | 97.0% |
| Aβ40 | 0.873 | 88.9% | 78.8% |
| Aβ42/40 | 0.736 | 53.3% | 90.9% |
| Total tau | 0.612 | 42.4% | 86.7% |
| NfL | 0.558 | 33.3% | 87.9% |
| Biomarker panel | | | | |
| Aβ42, Aβ40, Aβ42/40, NfL, and α-syn | 0.977 | 97.8% | 93.9% |
| Aβ42, Aβ40, Aβ42/40, and α-syn | 0.974 | 95.6% | 97.0% |
| Aβ42, Aβ40, and α-syn | 0.972 | 95.6% | 97.0% |
| APD vs. HC | Single biomarker | | | |
| NfL | 0.998 | 100% | 97.0% |
| α-Syn | 0.920 | 90.3% | 93.9% |
| Aβ42/40 | 0.721 | 80.0% | 81.8% |
| Aβ40 | 0.715 | 70.6% | 78.8% |
| Total tau | 0.711 | 75.0% | 75.8% |
| Aβ42 | 0.521 | 35.0% | 76.8% |
| Biomarker panel | | | | |
| NfL and α-syn | 1.000 | 100% | 100% |
| NfL and Aβ40 | 1.000 | 100% | 100% |
| NfL and Aβ42 | 1.000 | 100% | 100% |
| NfL and Aβ42/40 | 1.000 | 100% | 100% |
| NfL and total tau | 0.998 | 100% | 97.0% |
| MSA vs. HC | Single biomarker | | | |
| NfL | 1.000 | 100% | 100% |
| α-Syn | 0.990 | 100% | 93.9% |
| Total tau | 0.737 | 66.7% | 75.8% |
| Aβ42/40 | 0.720 | 66.7% | 75.6% |
| Aβ40 | 0.676 | 83.3% | 54.5% |
| Aβ42 | 0.513 | 58.3% | 57.6% |

(Continued)

plasma quantified by high-sensitivity immunoassays. Our results indicated that plasma NfL was significantly increased, and plasma total tau, Aβ42, and Aβ42/40 levels were lower in patients with APD than those in PD. NfL is an extraordinarily prospective biomarker as a single measure for differentiating APD (MSA and PSP) from PD and HCs as well as differentiating MSA from PSP, with high sensitivity and specificity. By means of adding NfL to the biomarker panel, the diagnostic accuracy of dramatically improved on visual inspection. According to our results, various combinations of these six biomarkers were able to differentiate PDSs from HC, APD from PD, and the subtypes of APD from one another. Furthermore, we performed the correlation analysis suggesting that there was a correlation observed between plasma Aβ with motor and cognitive function in APD. Together, a measurement of integrated biomarker panel has great potentialities of differential diagnosis in PDSs, and these potential biomarkers may be indicators of monitoring motor and cognitive progression in patients with PDSs.

NfL is the most important and abundant subunit in neurofilaments. Under normal conditions, NfL is released from axons, probably in an age-dependent manner, and increases with age (Disanto et al., 2017). However, on special occasions in response to CNS axonal damage, such as inflammatory, neurodegenerative, traumatic, or vascular injury, the release of NfL is notably rising (Gaetani et al., 2019). Our findings are consistent with those reported in previous studies (Gaetani et al., 2019; Marques et al., 2019; Archer et al., 2020). All the relevant studies mentioned previously verified that plasma NfL was significantly higher in APD than that in PD and thus proved to have diagnostic value in identifying APD.

Definitely, plasma and CSF amyloid β (ratio of amyloid β42 to amyloid β40) reflect brain amyloidosis (Nakamura et al., 2018; Schindler et al., 2019). Aβ peptides are important for neuronal information processing and are major constituents of amyloid plaques deposited in the brains of patients with Alzheimer’s disease (AD), but also seen in other neurodegenerative diseases and notably in patients accompanied with dementia (Gomperts et al., 2013). In this study, we
found plasma amyloid β was significantly higher in PDS compared with controls, consistent with those reported in previous studies (Seino et al., 2019). Moreover, our observations that plasma Aβ42 level positively correlated with global cognitive status in patients with APD further confirmed the close connection between amyloid β and cognitive dysfunction. However, another finding revealed that plasma Aβ42 levels were positively correlated to UPDRS part III in patients with MSA, despite no enough evidence for the correlation at present.

The major component of neurofibrillary tangles is the natively unfolded phosphoprotein tau. In human neurodegenerative diseases with filamentous deposits, such as AD, tau protein becomes hyperphosphorylated, as an initiating event preceding filament assembly (Lee et al., 2001). The imbalance of the tau isoforms with three (3R-tau) or four (4R-tau) microtubule-binding repeat domains contributes to the pathogenesis of neurodegeneration. Particularly, PSP is a 4R

### TABLE 3 | Discriminatory value of plasma NfL, total tau, Aβ42, Aβ40, Aβ42/40 and α-syn as a single biomarker and as part of plasma biomarker panel in differentiating PD from APD (MSA and PSP).

| Diagnostic groups | Predictor                  | AUC  | Sensitivity | Specificity |
|-------------------|---------------------------|------|-------------|-------------|
| PD vs. APD        | NfL                        | 0.963| 88.9%       | 95.0%       |
|                   | Aβ42                       | 0.924| 71.1%       | 100%        |
|                   | Total tau                  | 0.914| 80.0%       | 95.0%       |
|                   | Aβ42/40                    | 0.897| 73.0%       | 100%        |
|                   | Aβ40                       | 0.791| 73.3%       | 85.0%       |
|                   | α-Syn                      | 0.562| 55.6%       | 65.0%       |
| Biomarker panel   | NfL, Aβ42 and total tau    | 1.000| 100%        | 100%        |
|                   | NfL and total tau          | 0.996| 95.6%       | 100%        |
|                   | NfL, Aβ42 and Aβ42/40      | 0.990| 100%        | 95.6%       |
|                   | Aβ42, total tau, and Aβ42/40| 0.981| 100%        | 88.9%       |
| PD vs. MSA        | NfL                        | 0.983| 100%        | 95.6%       |
|                   | Aβ42                       | 0.961| 88.9%       | 100%        |
|                   | Total tau                  | 0.930| 80.0%       | 100%        |
|                   | Aβ42/40                    | 0.896| 77.8%       | 100%        |
|                   | Aβ40                       | 0.850| 78.9%       | 100%        |
|                   | α-Syn                      | 0.600| 55.6%       | 65.0%       |
| Biomarker panel   | NfL, total tau, and Aβ42/40| 1.000| 100%        | 100%        |
|                   | NfL and total tau          | 0.998| 100%        | 97.8%       |
|                   | Aβ42 and total tau         | 0.985| 91.1%       | 100%        |
| PD vs. PSP        | NfL                        | 0.993| 82.5%       | 100%        |
|                   | Aβ42/40                    | 0.897| 73.3%       | 100%        |
|                   | Total tau                  | 0.892| 82.2%       | 87.5%       |
|                   | Aβ42                       | 0.869| 71.1%       | 100%        |
|                   | Aβ40                       | 0.703| 62.2%       | 75.0%       |
|                   | α-Syn                      | 0.506| 62.3%       | 37.5%       |
| Biomarker panel   | NfL, Aβ42/40, and total tau| 1.000| 100%        | 100%        |
|                   | NfL, total tau, and Aβ42/40| 1.000| 100%        | 100%        |
|                   | NfL and total tau          | 0.992| 95.6%       | 100%        |
|                   | NfL and Aβ42/40            | 0.978| 95.6%       | 100%        |
|                   | NfL and Aβ42               | 0.967| 93.3%       | 100%        |

APD, atypical parkinsonian disorders; PD, Parkinson’s disease; MSA, multiple system atrophy; PSP, progressive supranuclear palsy; HC, healthy controls; NfL, neurofilament light chain; Aβ42, β-amyloid 42; Aβ40, β-amyloid 40; Aβ42/40, β-amyloid 42/40; Aβ40, β-amyloid 40; Aβ42/40, β-amyloid 42/40; AUC, area under the curve; α-syn, α-synuclein.

### TABLE 4 | Discriminatory value of plasma NfL, total tau, Aβ42, Aβ40, Aβ42/40 and α-syn as a single biomarker and as part of plasma biomarker panel in differentiating MSA from PSP.

| Diagnostic groups | Predictor                  | AUC  | Sensitivity | Specificity |
|-------------------|---------------------------|------|-------------|-------------|
| MSA vs. PSP       | NfL                        | 0.802| 78.3%       | 87.5%       |
|                   | Aβ40                       | 0.698| 83.3%       | 62.5%       |
|                   | Aβ42                       | 0.594| 100%        | 50.0%       |
|                   | Total tau                  | 0.583| 82.2%       | 57.5%       |
|                   | Aβ42/40                    | 0.573| 58.5%       | 63.8%       |
|                   | α-Syn                      | 0.551| 50.0%       | 67.6%       |
| Biomarker panel   | NfL, total tau, Aβ42, Aβ40, and Aβ42/40| 1.000| 100%        | 100%        |
|                   | NfL, total tau, Aβ42, Aβ40, Aβ42/40, and α-syn | 1.000| 100%        | 100%        |
|                   | NfL, total tau, Aβ42, Aβ40, Aβ42/40, and α-syn | 0.844| 83.3%       | 87.5%       |
|                   | Total tau, Aβ42, Aβ40, and Aβ42/40 | 0.823| 91.7%       | 62.5%       |

MSA, multiple system atrophy; PSP, progressive supranuclear palsy; HC, healthy controls; NfL, neurofilament light chain; Aβ42, β-amyloid 42; Aβ40, β-amyloid 40; Aβ42/40, β-amyloid 42/40; AUC, area under the curve; α-syn, α-synuclein.

### TABLE 5 | The best single biomarker and panel in comparing different parkinsonian syndromes with each other and controls.

| Diagnostic groups | Single biomarker | AUC  | Panel  | AUC  |
|-------------------|------------------|------|--------|------|
| PDS-HC            | α-Syn            | 0.889| Aβ42, Aβ40, Aβ42/40, NfL, and α-syn | 0.983|
| PD-HC             | Aβ42             | 0.925| Aβ42, Aβ40, Aβ42/40, NfL, and α-syn | 0.977|
| APD-HC            | NfL              | 0.998| NfL and α-syn or Aβ42 or Aβ40 or Aβ42/40 | 1|
| MSA-HC            | NfL              | 1    | NA     | NA   |
| PSP-HC            | NfL              | 0.996| NfL and α-syn or Aβ42 or Aβ40 or Aβ42/40 | 1|
| PD-APD            | NfL              | 0.963| NfL, Aβ42 and total tau | 1|
| PD-MSA            | NfL              | 0.983| NfL, Aβ42/40, and total tau | 1|
| PD-PSP            | NfL              | 0.993| NfL, total tau, and Aβ42/40 or Aβ42 | 1|
| MSA-PSP           | NfL              | 0.802| NfL, total tau, Aβ42, Aβ40, and Aβ42/40 | 1|

PDS, parkinsonian syndrome; APD, atypical parkinsonian disorders; PD, Parkinson’s disease; MSA, multiple system atrophy; PSP, progressive supranuclear palsy; HC, healthy controls; NfL, neurofilament light chain; Aβ42, β-amyloid 42; Aβ40, β-amyloid 40; Aβ42/40, β-amyloid 42/40; AUC, area under the curve; α-syn, α-synuclein; NA, not available.
tau neuropathological entity. Several studies have reported that elevated total tau levels in CSF may help to distinguish PDSs (Süssmuth et al., 2010; Aerts et al., 2011), whereas no such comparable findings were observed in blood (Lin et al., 2018; Li et al., 2021). Furthermore, total tau may be an indicator of cognition. Total tau protein levels have been applied to discriminate dementia with Lewy bodies and PD dementia (PDD) from AD (Howard et al., 2021). However, in our study, measurement of plasma total tau alone was not able to achieve good diagnostic value. Possible explanations may be due to the limited number of patients enrolled and deficient measurement of phosphorylated tau protein.

Our results highlight that plasma NfL is an extraordinarily prospective biomarker as a single measure for differentiating PDSs, whereas other plasma biomarker measurements could not reach an ideal diagnostic value. A combination of α-syn, Aβ42, Aβ40, Aβ42/40, and NfL could achieve a best diagnostic value in differentiating PDS from HC and PD from HC. As we speculated, by adding NfL to measurements of other biomarker models, there was an obvious improvement in differentiating APD patients from PD and HC. When adding NfL to measurements of α-syn, Aβ42, Aβ40, or Aβ42/40, the best discriminating panel was formed in differentiating APD and HC with a sensitivity of 100% and specificity of 100%, and combination of NfL, Aβ42, and total tau was proved to be the most reliable panel for differential diagnosis between PD and APD, with equally high diagnostic accuracy. For differentiating the subtypes of APD from one another, our results revealed that measurement of NfL, total tau, Aβ42, Aβ40, and Aβ42/40 was the best discriminating panel. Our findings of improved discriminatory potential using a biomarker panel confirm that the combination of NfL with other plasma biomarkers could differentiate PDSs more accurately than a single blood biomarker.

The major strength of our present study was that we evaluated the diagnostic value of several specific plasma biomarkers (NfL, total tau, Aβ42, Aβ40, Aβ42/40 and α-syn) for discriminating PDSs. Combining multiple blood-based biomarkers considerably increases the diagnostic sensitivity and specificity. Simultaneously, we conducted the correlation analysis of plasma biomarkers with motor symptom and cognition. However, there are some limitations to our present study. First, final diagnoses of our participants were established based on clinical evaluations rather than neuropathological confirmation, which increased the possibility of misclassification. Second, the relatively restricted number of patients and lack of follow-up and tracking the changes of biomarkers over time may limit the clinical application to PDS patients. Third, there were significant differences in clinical characteristics among different groups, for which we interpret that the diagnostic groups we enrolled are heterogeneous; namely, the disease severity is diverse among different PDSs, embodied in motor symptoms (H&Y stage, MDS-UPDRS III) and non-motor features (cognitive impairment, sleep disorders, and mood disturbances). For this reason, bias may arise. Finally, a combination of other candidate biomarkers, including CSF, serum, saliva, and skin, would be an enhancement in diagnosis accuracy.

FIGURE 2 | Correlation between plasma Aβ42 and UPDRS part III scores in patients with MSA. The levels of plasma Aβ42 were positively related to UPDRS part III (r = 0.589, p = 0.03). MSA, multiple system atrophy; Aβ42, β-amyloid 42; UPDRS part III, Unified Parkinson’s Disease Rating Scale part III.

FIGURE 3 | Scatter plot showing the relationship between plasma Aβ42/40 level and MMSE scores in the MSA group (Left) and PSP group (Right). Solid line indicates a correlation observed between Aβ42/40 level and global cognitive status in patients with APD (MSA: r = 0.593, p = 0.03; PSP: r = 0.763, p = 0.03). MSA, multiple system atrophy; PSP, progressive supranuclear palsy; Aβ42/40, β-amyloid 42/40; MMSE, Mini-Mental State Examination.
CONCLUSION
Our findings support the use of a panel of biomarkers to differentiate PDs from HC, APD from PD, and the subtypes of APD from one another. Plasma NfL is an extraordinarily prospective biomarker contributing to a biomarker panel in discriminating APD patients from PD and HC and discriminating different subtypes of APD. This outcome may have essential clinical benefit in terms of improving diagnostic accuracy of PDs. Further large-scale, longitudinal follow-up studies are needed to evaluate the differential value of these integrated plasma biomarkers and validate whether plasma biomarkers levels could be applied to predict progression of motor and non-motor symptoms in patients with PDs.

DATA AVAILABILITY STATEMENT
The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding author.

ETHICS STATEMENT
The studies involving human participants were reviewed and approved by the Ethics Committee of the General Hospital of Tianjin Medical University. The patients/participants provided their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS
QL: conceptualization, methodology, software, formal analysis, writing – original draft, and writing – review and editing. ZheL: investigation, resources, methodology, data curation, software, and writing-original draft. XH, XS, FW, LB, ZhuL, RZ, and YW: investigation, validation, and writing – review and editing. XZ: supervision, project administration, and funding acquisition. All authors read and approved the final version of the manuscript.

FUNDS
This work was supported by Science & Technology Development Fund of Tianjin Education Commission for Higher Education under grants 2017ZD10, Tianjin Natural Science Foundation under grants 19JCZDJC35300, and Tianjin Health Commission under grants KJ20009.

ACKNOWLEDGMENTS
QL and ZheL are the first author in parallel. The collection and sharing of data for this study were done by ZheL, and the processing and analysis of data were completed by QL.

REFERENCES
Aerts, M. B., Esselink, R. A., Bloem, B. R., and Verbeek, M. M. (2011). Cerebrospinal fluid tau and phosphorylated tau protein are elevated in corticobasal syndrome. Mov. Disord. 26, 169–173. doi: 10.1002/mds.23541
Archer, D. B., Mitchell, T., Burciu, R. G., Yang, J., Nigro, S., Quattrone, A., et al. (2020). Magnetic Resonance Imaging and Neurofilament Light in the Differentiation of Parkinsonism. Mov. Disord. 35, 1388–1395. doi: 10.1002/mds.28060
Disanto, G., Barro, C., Benkert, P., Naegeli, Y., Schädelin, S., Giardiello, A., et al. (2017). Swiss Multiple Sclerosis Cohort Study Group. Serum Neurofilament light: a biomarker of neuronal damage in multiple sclerosis. Ann. Neurol. 81, 857–870. doi: 10.1002/ana.24954
Gaetani, L., Blennow, K., Calabresi, P., Di Filippo, M., Parmetti, L., and Zetterberg, H. (2019). Neurofilament light chain as a biomarker in neurological disorders. J. Neurol. Neurosurg. Psychiatry 90, 870–881. doi: 10.1136/jnnp-2018-320106
Grut, H., Hepp, D. H., Foncke, E., Berendse, H. W., Rozemuller, J. M., Huitinga, I., et al. (2020). Neuropathological correlates of parkinsonian disorders in a large Dutch autopsy series. Acta Neuropathol. Commun. 8:39. doi: 10.1186/s40478-020-00914-9
Gilman, S., Wenning, G. K., Low, P. A., Brooks, D. J., Mathias, C. J., Trojanowski, J. Q., et al. (2008). Second consensus statement on the diagnosis of multiple system atrophy. Neurology 71, 670–676. doi: 10.1212/01.wnl.0000324625.00404.15
Goetz, C. G., Tilley, B. C., Shaftman, S. R., Stebbins, G. T., Fahn, S., Martinez-Martin, P., et al. (2008). Movement Disorder Society UPDRS Revision Task Force. Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov. Disord. 23, 2129–2170. doi: 10.1002/mds.22340
Gomperts, S. N., Locascio, J. J., Rentz, D., Santarasci, A., Marquie, M., Johnson, K. A., et al. (2013). Amyloid is linked to cognitive decline in patients with Parkinson’s disease without dementia. Neurology 80, 85–91. doi: 10.1212/WNL.0b013e31827b1a07
Hoehn, M. M., and Yahr, M. D. (1967). Parkinsonism: onset, progression and mortality. Neurology 17, 427–442. doi: 10.1212/wnl.17.5.427
Howard, E., Irwin, D. J., Rascovsky, K., Nevler, N., ShelliKer, S., Tropea, T. F., et al. (2021). Cognitive Profile and Markers of Alzheimer Disease-Type Pathology in Patients With Lewy Body Dementias. Neurology 96, e1855–e1864. doi: 10.1212/WNL.0000000000011699
Hughes, A. J., Daniel, S. E., Kilford, L., and Lees, A. J. (1992). Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J. Neurol. Neurosurg. Psychiatry 55, 181–184. doi: 10.1136/jnnp.55.3.181
Lee, V. M., Goedert, M., and Trojanowski, J. Q. (2001). Neurodegenerative tauopathies. Annu. Rev. Neurosci. 24, 1121–1159. doi: 10.1146/annurev.neuro.24.1.1121
Li, C. H., Chen, T. F., Chiu, M. I., Yen, R. F., Shih, M. C., and Lin, C. H. (2021). Integrated 18F-T807 Tau PET, Structural MRI, and Plasma Tau in Tauopathy Neurodegenerative Disorders. Front. Aging Neurosci. 13:646440. doi: 10.3389/fnagi.2021.646440
Lin, C. H., Yang, S. Y., Horng, H. E., Yang, C. C., Chieh, J. J., Chen, H. H., et al. (2018). Plasma Biomarkers Differentiate Parkinson’s Disease From Atypical Parkinsonism Syndromes. Front. Aging Neurosci. 10:123. doi: 10.3389/fnagi.2018.00123
Marques, T. M., van Rumund, A., Oeckl, P., Kuiperij, H. B., Esselink, R. A. J., Bloem, B. R., et al. (2019). Serum NFL discriminates Parkinson’s disease from atypical parkinsonisms. Neurology 92, e1479–e1486. doi: 10.1212/WNL.0000000000017179
Nakamura, A., Kaneko, N., Villemagne, V. L., Kato, T., Doecke, J., Doré, V., et al. (2018). High performance plasma amyloid-β biomarkers for Alzheimer's disease. *Nature* 554, 249–254. doi: 10.1038/nature25456

Oosterveeld, L. P., Verberk, I. M. W., Majbour, N. K., El-Agnaf, O. M., Weinstein, H. C., Berendse, H. W., et al. (2020). CSF or serum neurofilament light added to α-Synuclein panel discriminates Parkinson's from controls. *Mov. Disord.* 35, 288–295. doi: 10.1002/mds.27897

Osaki, Y., Ben-Shlomo, Y., Lees, A. J., Daniel, S. E., Colosimo, C., Wenning, G., et al. (2004). Accuracy of clinical diagnosis of progressive supranuclear palsy. *Mov. Disord.* 19, 181–189. doi: 10.1002/mds.10680

Parnetti, L., Gaetani, L., Eusebi, P., Piacentini, S., Hansson, O., El-Agnaf, O., et al. (2019). CSF and blood biomarkers for Parkinson's disease. *Lancet Neurol.* 18, 573–586. doi: 10.1016/S1474-4422(19)30024-9

Schindler, S. E., Bollinger, J. G., Ovod, V., Mawuenyega, K. G., Li, Y., Gordon, B. A., et al. (2019). High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis. *Neurology* 93, e1647–e1659. doi: 10.1212/WNL.0000000000008081

Seino, Y., Nakamura, T., Kawarabayashi, T., Hirohata, M., Narita, S., Wakasaya, Y., et al. (2019). Cerebrospinal Fluid and Plasma Biomarkers in Neurodegenerative Diseases. *J. Alzheimers Dis.* 68, 395–404. doi: 10.3233/JAD-181152

Süssmuth, S. D., Uttner, I., Landwehrmeyer, B., Pinkhardt, E. H., Brettschneider, J., Petzold, A., et al. (2010). Differential pattern of brain-specific CSF proteins tau and amyloid-β in Parkinson's syndromes. *Mov. Disord.* 25, 1284–1288. doi: 10.1002/mds.22895

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher's Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Li, Li, Han, Shen, Wang, Bai, Li, Zhang, Wang and Zhu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.